Posted by Michael Wonder on 30 May 2019
Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly longer.
Hoffmann-La Roche announced today that Health Canada has approved Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC), with no epithelial growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.
This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with bevacizumab and chemotherapy (carboplatin and paclitaxel) helped people live significantly longer, compared with bevacizumab and chemotherapy alone (median overall survival was 19.2 versus 14.7 months; hazard ratio was 0.78; 95% CI: 0.64–0.96; p=0.0164) in the intention-to-treat wild-type population.
